Stop Chinese Fentanyl Act of 2025
Key claim: The Stop Chinese Fentanyl Act of 2025 would treat certain Chinese entities and senior officials who produce, sell, or abet trafficking of synthetic opioids as foreign opioid traffickers subject to mandatory sanctions, extend annual trafficker reporting through 2029, and require a published cost-benefit analysis before IEEPA economic regulations issued for a drug-trafficking national emergency.
Abstract
(HR747 · 119th Congress) Stop Chinese Fentanyl Act of 2025 This bill subjects certain Chinese entities and government officials to potential sanctions related to opioid trafficking and requires the President to conduct certain preliminary analyses before regulating economic transactions in the event of a national emergency related to international drug trafficking. Specifically, for the purposes of the Fentanyl Sanctions Act, the bill changes the definition of foreign opioid trafficker to specify that the term includes (1) Chinese entities involved in the production or sale of synthetic opioids or related pharmaceutical ingredients that fail to take steps to detect or prevent opioid trafficking; and (2) certain senior Chinese government officials that aid and abet opioid trafficking, including through intentional inaction. Under current law, the President must impose certain sanctions on individuals and entities identified as foreign opioid traffickers. Further, the bill extends through 2029 an existing requirement that the President report to Congress annually on identified foreign opioid traffickers and any sanctions imposed on them. (This requirement expired in December 2024.) The bill also requires the President to take additional steps in issuing regulations under the International Emergency Economic Powers Act (IEEPA) pursuant to a declared national emergency related to international drug trafficking. (IEEPA authorizes the President to regulate a variety of economic transactions following a declaration of national emergency.) Under the bill, the President must evaluate the costs and benefits of issuing economic regulations for the purpose of resolving the drug trafficking emergency and publish a discussion of such costs and benefits. Latest action (2025-09-03): Received in the Senate and Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
Why this matters
The bill would extend U.S. secondary-sanctions exposure to Chinese chemical producers, exporters, and PRC officials tied to fentanyl precursor flows, potentially disrupting legitimate chemical and pharmaceutical trade counterparties who transact with designated entities. Its IEEPA cost-benefit publication requirement would add a procedural check on future emergency economic regulations targeting drug-trafficking supply chains, affecting how quickly Treasury can deploy new trade restrictions. For importers and financial institutions, mandatory-designation triggers increase due-diligence burdens on China-sourced precursor and pharmaceutical trade.